News

August 22, 2018

ALX148 Blocks CD47 and Enhances Innate and Adaptive Antitumor Immunity with a Favorable Safety Profile  View article (PLOS ONE)

June 24, 2018

VIDEO LINK: ALX148 Clinical Program Overview By Sophia Randolph, MD, PhD, Chief Medical Officer at ALX Oncology  View video (Healio)

June 22, 2018

Alexo Therapeutics Changes Name to ALX Oncology   Read more   Download

June 4, 2018

Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma   Read more   Download

May 17, 2018

Alexo Therapeutics Initiates ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors and Lymphoma   Read more   Download

December 9, 2017

Alexo Therapeutics Presents Preclinical Data Demonstrating that ALX148 Bridges Innate and Adaptive Immunity to Enhance Antitumor Immune Response at the 59th Annual ASH Meeting   Read more   Download

November 13, 2017

Alexo Therapeutics to Present ALX148 Preclinical Data at the 59th American Society of Hematology Annual Meeting (ASH)  Read more   Download

November 10, 2017

Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma  Read more   Download

October 5, 2017

Alexo Therapeutics to Present ALX148 Clinical Data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)  Read more   Download

April 10, 2017

Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma  Read more   Download

July 25, 2016

BioCentury Emerging Company Profile of Alexo Therapeutics  Read article

Upcoming Events

No events scheduled at this time.